Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

5.43EUR
19 Feb 2018
Change (% chg)

-- (--)
Prev Close
€5.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
415,996
52-wk High
€12.89
52-wk Low
€4.33

Latest Key Developments (Source: Significant Developments)

Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - INNATE PHARMA SA ::INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD.  Full Article

Eric Vivier Joins Innate Pharma As Chief Scientific Officer
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Innate Pharma Sa ::REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER.  Full Article

Innate Pharma provides an update on lirilumab
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - INNATE PHARMA SA ::REG-INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB.‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS.COMBINATION OF NIVOLUMAB PLUS LIRILUMAB IN EXTENDED POPULATION OF PATIENTS WITH SCCHN DID NOT PROVIDE CLEAR EVIDENCE OF BENEFIT TO PATIENTS OR OBVIOUS DEVELOPMENT PATH.‍‍ON COMBINATION OF NIVOLUMAB PLUS LIRILUMAB: DISCUSSIONS ARE ONGOING REGARDING NEXT STEPS.AN UPDATE IS PLANNED FOR EARLY 2018​.  Full Article

Innate Pharma Q3 revenue up at 12.4 million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - INNATE PHARMA SA ::Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO.9 MONTH REVENUE EUR 27.9 MILLION VERSUS EUR 27.9 MILLION YEAR AGO.CASH POSITION AT SEPT 30 EUR 195.7 MILLION VERSUS EUR 239.6 MILLION YEAR AGO.  Full Article

Innate Pharma H1 operating loss widens to 18.2 million euros
Monday, 18 Sep 2017 

Sept 18 (Reuters) - INNATE PHARMA SA ::‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS(1) FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​.‍A NET LOSS FOR FIRST HALF OF 2017 AMOUNTING TO EUR 23.4M (EUR 3.2M FOR FIRST HALF OF 2016).​.H1 REVENUE EUR 21.3 MILLION VERSUS EUR 20.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 18.2 MILLION VERSUS LOSS OF EUR 2.9 MILLION YEAR AGO.  Full Article

Innate Pharma and Orega Biotech present preclinical data on IPH52
Tuesday, 19 Apr 2016 

Innate Pharma SA:Innate Pharma and Orega Biotech presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program.Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models.  Full Article

Innate Pharma presents new preclinical data supporting development of IPH4301
Monday, 18 Apr 2016 

Innate Pharma SA:New preclinical data further supporting development of IPH4301 presented at AACR meeting.Presented a new set of preclinical data further validating potential of its first-in-class anti-mica/b antibody IPH4301.  Full Article

Innate Pharma says DSMB meeting recommends continuation of EffiKIR trial
Wednesday, 16 Mar 2016 

Innate Pharma SA:Sixth DSMB meeting of the EffiKIR trial recommends continuation without modification.Data on primary endpoint, leukemia-free survival, are expected in second half of 2016.  Full Article

BRIEF-Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board

* INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD Source text for Eikon: Further company coverage: (Gdynia Newsroom)